12 terminated. 12 Phase 1, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 12 | Terminated 12 |
| Phase 2 | 6 | Terminated 6 |
Follow Bronchitis: new trials by email Literature Review of Bronchitis trials Research Report on Bronchitis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Upfront Ruxolitinib for Chronic Graft-vs-host Disease Ruxolitinib - Chronic Graft Versus Host Disease | Phase 1 | Terminated | Children's Hospital Medical Center, Cincinnati | 1 | 2025-02-19 | 2026-02-25 |
| Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome After Donor Hematopoietic Cell Transplant Itacitinib, Itacitinib Adipate - Bronchiolitis Obliterans | Phase 1 | Terminated | M.D. Anderson Cancer Center | 8 | 2021-10-08 | 2025-11-10 |
| Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation Itacitinib - Bronchiolitis Obliterans Syndrome | Phase 1 / Phase 2 | Terminated | Incyte Corporation | 23 | 2020-02-04 | 2025-10-20 |
| Glasdegib for Chronic Graft-Versus-Host Disease Glasdegib - Chronic Graft Versus Host Disease, Fasciitis | Phase 1 / Phase 2 | Terminated | Fred Hutchinson Cancer Center | 15 | 2019-12-03 | 2024-10-29 |
| Human IL-15 (rhIL-15) and Obinutuzumab for Relapsed and Refractory Chronic Lymphocyte Leukemia rhIL-15, Obinutuzumab - Leukemia, Lymphocytic | Phase 1 | Terminated | National Cancer Institute (NCI) | 1 | 2019-07-11 | 2022-03-22 |
| Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT Ibrutinib, Rituximab - Chronic Graft-versus-host-disease | Phase 1 / Phase 2 | Terminated | Dartmouth-Hitchcock Medical Center | 2 | 2019-04-11 | 2023-11-28 |
| Infasurf®(Calfactant) Aerosol for Infants With Bronchiolitis-AERO-04 Aerosolized Infasurf - Bronchiolitis | Phase 1 | Terminated | ONY | 13 | 2019-01-12 | 2020-10-23 |
| Acupuncture Chemotherapy-Induced Peripheral Neuropathy (CIPN) IRG Acupuncture, Questionnaires, Hand Function and Balance Tests - Breast Cancer | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 4 | 2014-07-06 | 2018-01-12 |
| Phase I Study of Milatuzumab for Graft Versus Host Disease milatuzumab - GVHD (Acute or Chronic), Acute Myeloid or Lymphoblastic Leukemia (AML or ALL) | Phase 1 | Terminated | Gilead Sciences | 12 | 2013-12-01 | 2021-08-19 |
| Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease Tocilizumab - Acute Graft Versus Host Disease | Phase 1 / Phase 2 | Terminated | Medical College of Wisconsin | 14 | 2011-08-08 | 2020-02-17 |
| A Study to Assess Safety, Tolerability and Pharmacokinetics of of AZD6553 in Healthy Volunteers and Patients With Chronic Obstructive Pulmonary Disease (COPD) AZD6553, Placebo - Chronic Obstructive Pulmonary Disease | Phase 1 | Terminated | AstraZeneca | 109 | 2010-02-01 | 2010-09-24 |
| Pharmacokinetic/Pharmacodynamic of Albinterferon Alfa-2b in Chronic Hepatitis B, eAg+, Infection Subjects albinterferon alfa-2b, Pegasys® - Chronic Hepatitis B | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 141 | 2009-07-01 | 2011-01-06 |
Bronchiolitis Obliterans Syndrome (10) · Breast Neoplasms (1) · Bronchiolitis (1) · Bronchiolitis Obliterans (1) · Fasciitis (1) · Graft vs Host Disease (1) · Hepatitis B (1) · Hepatitis B, Chronic (1) · Leukemia (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
Bronchial Diseases (12) · Lung Diseases (12) · Lung Diseases, Obstructive (12) · Respiratory Tract Diseases (12) · Bronchiolitis (11) · Bronchiolitis Obliterans (10) · Immune System Diseases (10) · Organizing Pneumonia (10) · Graft vs Host Disease (9) · Chronic Disease (3) · Disease Attributes (3) · Neoplasms (3) · Pathologic Processes (3) · Pathological Conditions, Signs and Symptoms (3)
INCB039110 (2) · itacitinib (2) · Acupuncture Therapy (1) · Interleukin-15 (1) · Rituximab (1) · Surveys and Questionnaires (1) · albinterferon alfa-2b (1) · calfactant (1) · glasdegib (1) · ibrutinib (1) · milatuzumab (1) · obinutuzumab (1) · peginterferon alfa-2a (1) · ruxolitinib (1) · tocilizumab (1)
M.D. Anderson Cancer Center (2) · AstraZeneca (1) · Children's Hospital Medical Center, Cincinnati (1) · Dartmouth-Hitchcock Medical Center (1) · Fred Hutchinson Cancer Center (1) · Gilead Sciences (1) · Incyte Corporation (1) · Medical College of Wisconsin (1) · National Cancer Institute (NCI) (1) · Novartis Pharmaceuticals (1) · ONY (1)
United States (10) · Belgium (1) · Canada (1) · China (1) · Hong Kong (1) · Poland (1) · Taiwan (1) · Thailand (1) · United Kingdom (1)
Amin Alousi, MD (1) · Joanna Marks-Konczalik (1) · John M Hill, MD (1) · Kay Garcia, DRPH (1) · Kevin C Conlon, M.D. (1) · Kevin O'Hayer, MD (1) · Pooja Khandelwal, MD (1) · Stephanie Lee (1) · T G K Mant, FRCP (UK) FFPM (1) · William R Drobyski, MD (1) · William Wegener, MD, PhD (1)
PMID 24995515, PMID 32508818, PMID 33883258, PMID 37698881
2009 (1), 2019 (1)